A study to evaluate XMT-1536 in cancer treatment

Trial Profile

A study to evaluate XMT-1536 in cancer treatment

Planning
Phase of Trial: Phase I

Latest Information Update: 09 Mar 2017

At a glance

  • Drugs XMT 1536 (Primary)
  • Indications Cancer; Non-small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Mar 2017 According to a Mersana Therapeutics media release, company expects clinical development of XMT-1536 in early 2018.
    • 09 Dec 2016 New trial record
    • 05 Dec 2016 According to a Mersana Therapeutics media release, the company anticipates to initiate this study later in the year 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top